Intelligent BIO Solutions Inc. key statistics and ratios

In fiscal 2026, Intelligent BIO Solutions Inc. had an operating margin of -299.1%, debt equal to 0.0% of equity and a current ratio of 1.44. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Intelligent BIO Solutions Inc.: financial ratios, annual
Fiscal year	2020Jun 2020	2021Jun 2021	2022Jun 2022	2023Jun 2023	2024Jun 2024	2025Jun 2025	2026Jun 2026
Gross margin	—	—	—	26.0%	45.8%	40.8%	48.6%
Operating margin	<−999%	−281.4%	<−999%	<−999%	−330.5%	−349.8%	−299.1%
Net margin	<−999%	−355.3%	<−999%	−845.9%	−326.4%	−346.2%	−294.9%
Free-cash-flow margin	—	—	—	—	−314.7%	−324.6%	−285.9%
Return on equity	—	−142.6%	−76.6%	—	−167.5%	−186.6%	—
Return on assets	−127.8%	−57.8%	−48.6%	−93.6%	−84.2%	−96.0%	−123.1%
Asset turnover	0.08	0.16	0.03	0.11	0.26	0.28	0.42
Current ratio	0.30	4.94	2.33	0.66	1.57	0.77	1.44
Debt to equity	—	0.0%	0.0%	19.9%	8.0%	6.6%	0.0%
Interest cover (operating income ÷ interest)	—	—	—	—	n/m	n/m	n/m
SG&A as % of revenue	—	—	—	—	—	292.2%	249.2%
Capital spending as % of revenue	—	—	—	—	7.1%	7.6%	3.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Intelligent BIO Solutions Inc.: financial ratios, quarterly
Quarter	2025 Q1Sept 2024	2025 Q2Dec 2024	2025 Q3Mar 2025	2025 Q4Jun 2025	2026 Q1Sept 2025	2026 Q2Dec 2025	2026 Q3Mar 2026	2026 Q4Jun 2026
Gross margin	34.7%	30.1%	37.8%	81.7%	46.6%	51.3%	50.5%	46.8%
Operating margin	−273.0%	−305.5%	−283.8%	−756.1%	−269.8%	−293.9%	−277.8%	−346.4%
Net margin	−269.0%	−303.5%	−281.9%	−752.1%	−268.3%	−298.6%	−269.9%	−341.0%
Free-cash-flow margin	—	—	—	—	−262.4%	−182.4%	−407.0%	−277.7%
Current ratio	1.14	0.92	1.12	0.77	0.89	2.37	2.11	1.44
SG&A as % of revenue	—	244.1%	267.7%	662.8%	—	260.6%	231.8%	260.9%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026

What it owns · $12m

Short-term assets $7mLonger-term assets $5m

What it owes, and who funded it · $12m

Short-term liabilities $5mLonger-term liabilities $2mShareholders' equity $6m

Short-term assets cover short-term liabilities $7m of assets due within a year against $5m of liabilities due within a year.
Short-term assets cover long-term liabilities $7m short-term assets against $2m of longer-dated liabilities.
More cash than debt Cash or debt not separately reported. Not assessable.
Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
Operating profit covers interest at least five times over Operating income of −$13m against $67,654 of interest.

From Intelligent BIO Solutions Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: CNSY vs INBS BMRA vs INBS INBS vs MCTA ICCM vs INBS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Intelligent BIO Solutions Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Intelligent BIO Solutions Inc.